• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Synlogic Inc. filed SEC Form 8-K: Leadership Update

    12/20/24 8:40:56 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYBX alert in real time by email
    8-K
    false000152759900015275992024-12-172024-12-17

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 17, 2024

     

     

    SYNLOGIC, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-37566

    26-1824804

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    PO Box 30

     

    Winchester, Massachusetts

     

    01890

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (617) 659-2802

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    SYBX

     

    The NASDAQ Capital Market

    Preferred Stock Purchase Rights

     

    N/A

     

    The NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.



    Antoine Awad

    Separation Agreement

    As previously disclosed, Synlogic, Inc. (the “Company”) and Antoine Awad, Principal Executive Officer, agreed that Mr. Awad’s employment with the Company will terminate effective December 31, 2024 (the “Awad Separation”). In connection with the Awad Separation, the Company entered into a separation agreement with Mr. Awad on December 17, 2024, to be effective on December 18, 2024 (the “Awad Separation Agreement”). Pursuant to the terms of the Awad Separation Agreement, Mr. Awad’s employment with the Company will end on December 31, 2024 (the “Awad Departure Date”). Mr. Awad will assist the Company through the Awad Departure Date in the transition of work in connection with his duties as Principal Executive Officer of the Company. On December 20, 2024, the Company’s board of directors appointed Mary Beth Dooley, the Company’s Head of Finance, as the Principal Executive Officer and Principal Financial Officer of the Company, effective January 1, 2025.

    In consideration for, among other things, his compliance with certain restrictive covenants and a typical release of claims, Mr. Awad shall receive a lump-sum payment equal to $218,856, which is equivalent to six months of his base salary. Additionally, Mr. Awad will be eligible for consideration of 100% of his target 2024 bonus. Mr. Awad will also receive a lump-sum payment equivalent to 75% of his base salary for each month of service to the Company between March 1, 2024 and December 31, 2024, or $246,213. Mr. Awad is also entitled to continued health insurance coverage for up to six months following the Awad Departure Date.

    The foregoing description of the material terms of the Awad Separation Agreement is qualified in its entirety by the full text of the Awad Separation Agreement, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the year ending December 31, 2024.

     

    Consulting Agreement

    The Company entered into a Consulting Agreement (the “Awad Consulting Agreement”) with Mr. Awad, as amended, pursuant to which Mr. Awad will perform consulting and other project-based services for the Company as determined by the Company’s board of directors. The Company will pay Mr. Awad an hourly rate of $350.00 per hour for such services and will reimburse Mr. Awad for expenses. The Consulting Agreement’s term continues until either party gives notice of termination. Pursuant to the Awad Consulting Agreement, the terms of previous grants of shares of restricted stock and stock options to Mr. Awad (the “Awad Equity Grants”) granted pursuant to the Company’s 2015 Equity Incentive Award Plan and 2017 Stock Incentive Plan, were amended to (a) extend the exercise period of such options for a period of 90 days after the termination of the Awad Consulting Agreement, (b) allow the withholding of an appropriate amount of shares of restricted stock to satisfy tax withholding obligations and (c) accelerate the unvested portion of the Awad Equity Grants upon the earlier of (i) the Company’s dissolution and (ii) the consummation of a Change in Control (as defined in the Awad Consulting Agreement). Pursuant to the Awad Consulting Agreement, the Awad Equity Grants shall otherwise remain subject to the original terms and conditions of such awards, and any unvested portions of such awards which would otherwise be forfeited upon the Awad Departure Date shall remain eligible for continued vesting, contingent upon the timely execution of the Awad Consulting Agreement and so long as Mr. Awad continues to provide services under the Awad Consulting Agreement.

    The foregoing summary of the Awad Consulting Agreement does not purport to be complete and is subject to, and qualified in its entirety by the full text of the Awad Consulting Agreement, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the year ending December 31, 2024.

     


     

    Mary Beth Dooley

    On December 19, 2024, and in connection with the Awad Separation, the Company appointed Mary Beth Dooley, Head of Finance, as the Principal Executive Officer and Principal Financial Officer, effective as of January 1, 2025. Ms. Dooley’s biographical information can be found under the caption “Management and Corporate Governance” in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on November 6, 2024, and such biographical information is incorporated herein by reference.

    The Company entered into an amendment to the Employment Letter Agreement (the “Amended Employment Agreement”) with Ms. Dooley on December 19, 2024, pursuant to which Ms. Dooley will perform duties and responsibilities associated with her position as Principal Executive Officer and Principal Financial Officer of the Company. The Company will pay Ms. Dooley a base salary of $325,000 per year, and her target annual bonus in respect of the 2024 calendar year of 30% of her annual base salary, or $97,500.

    Ms. Dooley will not be eligible for any bonus in respect of 2025 or any subsequent year. Ms. Dooley shall also be eligible for a retention bonus in an amount equal to 75% of her base salary for each month of service to the Company between March 1, 2024 and the earlier of (i) the month in which the Company consummates a Change in Control (as defined in the Amended Employment Agreement) and (ii) the month in which the Company terminates her employment without Cause or she resigns her employment with Good Reason (each, as defined in the Amended Employment Agreement). Payment of the retention bonus is subject to Ms. Dooley entering into a separation agreement substantially in a form described in the Amended Employment Agreement. Pursuant to the Amended Employment Agreement, upon a termination of Ms. Dooley’s employment by the Company without Cause or her resignation of employment with Good Reason, subject to her execution of a separation agreement substantially in a form described in the Amended Employment Agreement, Ms. Dooley will be entitled to (i) continued payment of base salary for 9 months and (ii) payment by the Company of the Company portion of the premium for health coverage if she timely elects to continue receiving group medical insurance pursuant to COBRA. Pursuant to the Amended Employment Agreement, the Company also amended the terms of previous grants of shares of restricted stock and stock options (the “Dooley Equity Grants”) granted pursuant to the Company’s 2015 Equity Incentive Award Plan and 2017 Stock Incentive Plan, to (a) extend the exercise period of such options for a period of 90 days after the termination of the Amended Employment Agreement, (b) allow the withholding of an appropriate amount of shares of restricted stock to satisfy tax withholding obligations and (c) accelerate the unvested portion of the Dooley Equity Grants upon the earlier of (i) the Company’s dissolution, (ii) the consummation of a Change in Control and (iii) termination by the Company without Cause (as defined in the Amended Employment Agreement) or by Ms. Dooley for Good Reason (as defined in the Amended Employment Agreement).

    The foregoing summary of the Amended Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by the full text of the Amended Employment Agreement, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the year ending December 31, 2024.

    There is no arrangement or understanding with any person pursuant to which Ms. Dooley was appointed as the Principal Executive Officer and Principal Financial Officer of the Company. There are no transactions to which the Company is a party and in which Ms. Dooley has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K. Ms. Dooley has no family relationship with any directors or executive officers of the Company.

     

     

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    Date: December 20, 2024

    Synlogic, Inc.

     

     

     

    By:

    /s/ Mary Beth Dooley

     

     

    Name:

    Title:

    Mary Beth Dooley
    Head of Finance

    (Principal Financial Officer)

     

     


    Get the next $SYBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYBX

    DatePrice TargetRatingAnalyst
    11/24/2021$7.00Perform → Outperform
    Oppenheimer
    11/24/2021Perform → Outperform
    Oppenheimer
    11/11/2021$15.00 → $11.00Outperform
    SVB Leerink
    10/13/2021$9.00 → $7.00Buy
    HC Wainwright & Co.
    9/20/2021$7.00 → $9.00Overweight
    Piper Sandler
    6/28/2021$13.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SYBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Synlogic upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Synlogic from Perform to Outperform and set a new price target of $7.00

      11/24/21 7:28:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic upgraded by Oppenheimer

      Oppenheimer upgraded Synlogic from Perform to Outperform

      11/24/21 4:55:59 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Synlogic with a new price target

      SVB Leerink reiterated coverage of Synlogic with a rating of Outperform and set a new price target of $11.00 from $15.00 previously

      11/11/21 5:14:48 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:46:11 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Flynn James P was granted 15,000 shares (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:43:44 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dooley Mary Beth sold $173 worth of shares (144 units at $1.20), decreasing direct ownership by 1% to 12,901 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/3/25 4:30:42 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      11/14/24 4:40:57 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Synlogic Inc. (Amendment)

      SC 13D/A - SYNLOGIC, INC. (0001527599) (Subject)

      5/16/24 7:44:32 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Synlogic Inc.

      SC 13G - SYNLOGIC, INC. (0001527599) (Subject)

      4/18/24 11:18:42 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synlogic Reports Third Quarter 2024 Financial Results

      WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Synlogic Board of Di

      11/12/24 4:35:09 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports Second Quarter 2024 Financial Results

      WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetab

      8/8/24 7:00:52 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports First Quarter 2024 Financial Results

      CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetable fo

      5/14/24 7:00:28 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Synlogic Inc.

      10-Q - SYNLOGIC, INC. (0001527599) (Filer)

      5/8/25 4:30:30 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Synlogic Inc.

      10-K/A - SYNLOGIC, INC. (0001527599) (Filer)

      4/30/25 11:57:58 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Synlogic Inc.

      10-K - SYNLOGIC, INC. (0001527599) (Filer)

      3/6/25 4:47:33 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Financials

    Live finance-specific insights

    See more

    $SYBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Synlogic Adopts Limited Duration Stockholders Rights Plan

      CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025. The Company also

      2/20/24 12:15:26 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

      Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar across placebo and active arms Synlogic to host webcast today at 8:30 am. ET with Dr. Kyle Wood, Associate Professor, Urology,​ University of Alabama ​at Birmingham  CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB8802 has demonstrated proof of concept through clinically significant

      12/15/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

      Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of activity across all assessed endpoints Company confirms SYNB1934 as candidate for Phase 3 initiation expected in H1 2023 Synlogic to Host Webcast Today at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced positive top-line data from the Phase 2 Synpheny-1 study in phenylketonuri

      10/18/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

      – Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poster presentations at SIMD Annual Meeting – – $77.6 million in cash, cash equivalents and marketable securities support projected runway into second half of 2024 –    CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. "

      3/29/23 6:40:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

      CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. "Developing a new therapeutic modality requires seamless integration of research and clinical development so that learnings from the clinic can be immediately applied to earlier programs," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Since joining the company, Dave has demonstrated the attributes required

      1/3/23 6:58:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care